Matthew B Frieman Selected Research

Matthew B Frieman Research Topics

Disease

28	Infections 11/2023 - 01/2010
20	COVID-19 12/2023 - 01/2020
11	Virus Diseases (Viral Diseases) 01/2023 - 10/2010
4	Coronavirus Infections 05/2022 - 08/2014
4	Severe Acute Respiratory Syndrome 12/2017 - 01/2010
3	Human Influenza (Influenza) 11/2021 - 05/2015
3	Emerging Communicable Diseases (Emerging Infectious Diseases) 12/2017 - 02/2016
3	Lung Diseases (Lung Disease) 01/2017 - 02/2014
2	Insulin Resistance 11/2023 - 12/2022
2	Metabolic Diseases (Metabolic Disease) 11/2023 - 12/2022
2	Obesity 11/2023 - 12/2022
2	Neoplasms (Cancer) 12/2017 - 08/2014
2	Fibrosis (Cirrhosis) 01/2017 - 01/2017
2	Inflammation (Inflammations) 04/2015 - 04/2010
1	Atherosclerosis 01/2023
1	Reinfection 12/2022
1	Type 2 Diabetes Mellitus (MODY) 12/2022
1	Alzheimer Disease (Alzheimer's Disease) 09/2022
1	Necrosis 01/2022
1	Vesicular Stomatitis 01/2022
1	Bites and Stings (Sting) 05/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 02/2021
1	Rabies (Hydrophobia) 01/2017
1	Communicable Diseases (Infectious Diseases) 01/2017
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2017
1	Wounds and Injuries (Trauma) 01/2017
1	Lung Injury 01/2017
1	Pneumococcal Infections 05/2015
1	Arthritis (Polyarthritis) 04/2015
1	Hepatitis 08/2014

Drug/Important Bio-Agent (IBA)

12	VaccinesIBA 11/2023 - 01/2017
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2010
10	Antiviral Agents (Antivirals)IBA 12/2022 - 04/2014
6	Messenger RNA (mRNA)IBA 11/2023 - 11/2010
6	InterferonsIBA 10/2023 - 10/2010
4	mRNA VaccinesIBA 11/2023 - 01/2022
4	Neutralizing AntibodiesIBA 01/2022 - 07/2015
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2023 - 02/2014
3	remdesivirIBA 12/2022 - 06/2021
3	NucleosidesIBA 12/2022 - 06/2021
3	RNA (Ribonucleic Acid)IBA 09/2022 - 01/2011
3	CytokinesIBA 09/2022 - 01/2012
3	AntibodiesIBA 01/2022 - 07/2015
3	Viral RNAIBA 11/2021 - 09/2020
3	Phosphotransferases (Kinase)IBA 01/2018 - 02/2015
2	Protease Inhibitors (Protease Inhibitor)IBA 12/2022 - 10/2021
2	pyrimidineIBA 01/2022 - 06/2021
2	NVX-CoV2373 adjuvated lipid nanoparticleIBA 01/2021 - 12/2020
2	Carrier Proteins (Binding Protein)IBA 09/2020 - 05/2015
2	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 10/2016
2	Antipsychotic Agents (Antipsychotics)IBA 12/2017 - 08/2014
2	ErbB Receptors (EGF Receptor)IBA 01/2017 - 01/2017
2	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 11/2010 - 10/2010
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2023
1	Cyclic NucleotidesIBA 06/2023
1	SARS-CoV-2 ORF6 proteinIBA 01/2023
1	Immunoglobulin A (IgA)IBA 12/2022
1	nirmatrelvir and ritonavir drug combinationIBA 12/2022
1	apilimodIBA 12/2022
1	Neuropilin-1IBA 09/2022
1	Viral AntigensIBA 01/2022
1	FibrinIBA 01/2022
1	molnupiravirIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	EmulsionsIBA 05/2021
1	Pattern Recognition ReceptorsIBA 05/2021
1	Aluminum Hydroxide (Algeldrate)FDA Link 05/2021
1	Peptide Hydrolases (Proteases)FDA Link 02/2021
1	AntigensIBA 01/2021
1	Matrix-MIBA 01/2021
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 12/2020
1	Nucleic AcidsIBA 09/2020
1	Antisense OligonucleotidesIBA 01/2020
1	PhosphoproteinsIBA 01/2020
1	Sulfhydryl Compounds (Thiols)IBA 01/2020
1	GoldIBA 01/2020
1	Sirtuin 1IBA 01/2019
1	Antimalarials (Antimalarial Agents)IBA 12/2017
1	AmphiregulinIBA 01/2017
1	LigandsIBA 01/2017
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2017
1	NanovaccinesIBA 01/2017
1	hippuryl-glycyl-glycine (HIGG)IBA 02/2016
1	Polysaccharides (Glycans)IBA 05/2015
1	Neuraminidase (Sialidase)IBA 05/2015
1	LectinsIBA 05/2015
1	Galectin 3 (LGALS3)IBA 05/2015
1	Galectin 1 (LGALS1)IBA 05/2015
1	CarbohydratesIBA 05/2015
1	Galectins (Galectin)IBA 05/2015
1	celastrolIBA 04/2015
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2015
1	Mitogen-Activated Protein KinasesIBA 02/2015
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2015
1	TOR Serine-Threonine KinasesIBA 02/2015
1	Dopamine Receptors (Dopamine Receptor)IBA 08/2014
1	SSYA10-001IBA 08/2014

Therapy/Procedure

5	Therapeutics 10/2020 - 04/2015
1	Off-Label Use 10/2020